Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer (Q28288814)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18661530%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

title

Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18661530%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

main subject

metastatic breast cancer

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18661530%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

author name string

Suhail M Ali

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18661530%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Walter P Carney

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18661530%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Monica Fornier

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18661530%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Lyndsay Harris

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18661530%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Wolfgang J Köstler

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18661530%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Jean-Pierre Lotz

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18661530%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Diana Luftner

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18661530%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Marie-France Pichon

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18661530%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Allan Lipton

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18661530%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Serum HER-2/neu Study Group

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18661530%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

language of work or name

English

0 references

publication date

1 September 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18661530%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

number of pages

8

1 reference

inferred from page(s)

published in

Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18661530%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

volume

113

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18661530%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18661530%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

page(s)

1294-1301

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18661530%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23689

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23689

7 January 2021

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23689

7 January 2021

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23689

7 January 2021

Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23689

7 January 2021

Potential Clinical Utility of Serum HER-2/neu Oncoprotein Concentrations in Patients with Breast Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23689

7 January 2021

Serum HER-2/neu and Response to the Aromatase Inhibitor Letrozole Versus Tamoxifen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23689

7 January 2021

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23689

7 January 2021

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23689

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23689

7 January 2021

The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23689

7 January 2021

In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23689

7 January 2021

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23689

7 January 2021

Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23689

7 January 2021

Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23689

7 January 2021

Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23689

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23689

7 January 2021

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23689

7 January 2021

Herceptin: mechanisms of action and resistance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23689

7 January 2021

Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23689

7 January 2021

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23689

7 January 2021

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23689

7 January 2021

Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23689

7 January 2021

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23689

7 January 2021